CPhI MEA 2018

Latest Industry Press Releases More...

We bring you the latest pharmaceutical press releases in our pharmaceutical Industry Press Releases section to help our clients gain great exposure on industry happenings. Know about mergers, deals, technology release, and other information first hand from press conferences of industry leaders with our Global pharmaceuticals Industry Press Releases.

Regeneron Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). The sBLA was based on second-year data from the Phase 3 VIEW 1 and 2 trials…

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market…

SAB Biotherapeutics, Inc. (SAB) , a clinical-stage biopharmaceutical development company, announced today that its anti-Ebola immunotherapy (SAB-139) has been launched in a recent Animal study "100% protection against a lethal dose of the Ebola virus" was published in "The Journal of Infectious Diseases" . The study was funded by the…

Sun Pharmaceutical Industries Ltd., “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). CEQUA…

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy Designation is designed to…

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized…

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the State Intellectual Property Office of China has issued a Decision to Grant for Relmada's patent application number 201380061197.3, titled "d-Methadone for the Treatment of Psychiatric Symptoms". The patent…

Alector, a privately held biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development has granted orphan drug designation to AL001, a human recombinant monoclonal antibody, for the treatment…

Rite Aid Corporation today announced that it has mutually agreed with Albertsons Companies Inc. (“Albertsons”) to terminate their previously announced merger agreement. “While we believed in the merits of the combination with Albertsons, we have heard the views expressed by our stockholders and are committed to moving forward and executing…

XcellBio, a proprietary provider of primary cell control technologies for immunotherapeutic solutions today announced a collaboration with Carolina BioOncology Institute (CBI) to further pre-clinical development of true personalized medicine therapies. CBI will utilize XcellBio's products to expand and profile patient derived tumor and immune cells through the use of the…

loader